*Required field.
Thank you.
Your registration has been received and we will be in touch shortly.
*Required field.
EXPAND
VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
For more information about VILTEPSO, see full Prescribing Information.
For more information about VILTEPSO, see full Prescribing Information.
The information provided in this website is intended for U.S. healthcare professionals only. By continuing, you certify that you are a licensed healthcare professional.